Glasky A J, Gordon J F
Newport Institute for Medical Research, Newport Beach, CA.
Cancer Detect Prev Suppl. 1987;1:597-609.
The immunopharmacologic effects of Isoprinosine (INPX) have been associated with clinical benefit to the patient in a number of conditions characterized by immunodeficiency of diverse etiology. Immunodepressed homosexuals at risk of developing acquired immunodeficiency syndrome (AIDS) treated with placebo or INPX experienced an increase in the function and number of immunocompetent cells associated with clinical improvement. A multicenter trial designed to confirm these results has demonstrated that INPX produced an increase in natural killer (NK)-cell activity, total T cells, and T-helper cells, with certain effects persisting for months after completion of the 28-day treatment period. INPX-treated patients also experienced clinical improvement and decreased incidence of progression to AIDS. The administration of INPX for longer periods to patients with frank AIDS under a compassionate-use protocol has also proved useful. Clinical benefit associated with INPX treatment has been demonstrated in other patients with a depressed immune response, such as aged patients, cancer patients, severely burned patients, ill patients, and surgery patients. This program of clinical trials supports the therapeutic use of INPX in the treatment of AIDS and other acquired immunodeficiencies of clinical importance.
异丙肌苷（INPX）的免疫药理作用已在多种病因导致免疫缺陷的病症中显示出对患者具有临床益处。接受安慰剂或INPX治疗的有患获得性免疫缺陷综合征（AIDS）风险的免疫抑制同性恋者，其免疫活性细胞的功能和数量增加，临床症状改善。一项旨在证实这些结果的多中心试验表明，INPX可使自然杀伤（NK）细胞活性、总T细胞和辅助性T细胞增加，在28天治疗期结束后，某些效应可持续数月。接受INPX治疗的患者临床症状也有所改善，发展为AIDS的发生率降低。在同情用药方案下，对患有明显AIDS的患者长期给予INPX也已证明是有效的。在其他免疫反应低下的患者中，如老年患者、癌症患者、严重烧伤患者、患病患者和手术患者，也已证明INPX治疗具有临床益处。该临床试验项目支持INPX在治疗AIDS和其他具有临床重要性的获得性免疫缺陷方面的治疗用途。
